Eli Lilly’s, Boehringer Ingelheim’s Jardiance Reduces Risk of Heart-Related Death
Eli Lilly’s and Boehringer Ingelheim’s blockbuster diabetes drug Jardiance (empagliflozin) reduced the risk of heart-related death or hospitalization for adults suffering from heart failure with preserved ejection fraction, according to topline findings from a late-stage study.
The companies did not disclose data from the phase 3 trial, which enrolled nearly 6,000 patients, but said the results make Jardiance the first therapy to improve outcomes for the full range of heart failure patients regardless of ejection fraction — a measurement of the percentage of blood leaving the heart each time it contracts.
Jardiance is approved for treating type 2 diabetes and reducing the risk of cardiovascular disease for adults with type 2 diabetes.
Lilly reported global sales of $1.15 billion for the diabetes drug in 2020, while Boehringer posted worldwide Jardiance sales of $2.92 billion.